Company Description
Sentry Data Systems is a SaaS-based analytics, compliance and performance improvement platform providing its customers and their partners near real-time, actionable intelligence to enhance care delivery, optimize workflows, and reduce costs. Sentry’s core solutions support hospitals and their contract pharmacies in maximizing financial performance under the 340B Drug Discount Program by helping streamline drug procurement and utilization while maintaining strict program compliance. DataNext, Sentry’s latest solution, is an extremely powerful analytics platform that is capable of providing hospitals with granular cost-transparency insight that sheds light on the true cost of care.
Objectives
TripleTree was engaged as Sentry’s financial advisor to explore the Company’s strategic options and determine whether a new equity partner would benefit the company. In doing so, TripleTree helped Sentry evaluate potential partners and investors that would support the Company’s growth plan as well as accelerate its go-to-market strategy for DataNext. Throughout the process, TripleTree emphasized the extensibility of the Company’s platform beyond 340B compliance by highlighting the Company’s emerging suite of cost and performance analytics solutions as well as emphasized the stability and long-term sustainability of the 340B program.
Results
The Company received strong interest from the buyer universe, and ABRY Partners, a middle-market private equity firm focused on healthcare information systems, media and communications, ultimately emerged as the ideal partner for Sentry. ABRY appreciates the strength of Sentry’s core business and management team as well as sees significant upside in its emerging cost-transparency solutions.